SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-003131
Filing Date
2022-11-10
Accepted
2022-11-10 16:04:50
Documents
69
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrkr-20220930x10q.htm   iXBRL 10-Q 1344583
2 EX-31.1 mrkr-20220930xex31d1.htm EX-31.1 15691
3 EX-31.2 mrkr-20220930xex31d2.htm EX-31.2 15868
4 EX-32.1 mrkr-20220930xex32d1.htm EX-32.1 7664
5 EX-32.2 mrkr-20220930xex32d2.htm EX-32.2 7689
6 GRAPHIC mrkr-20220930x10q001.jpg GRAPHIC 9834
7 GRAPHIC mrkr-20220930x10q002.jpg GRAPHIC 51317
  Complete submission text file 0001410578-22-003131.txt   5652470

Data Files

Seq Description Document Type Size
8 EX-101.SCH mrkr-20220930.xsd EX-101.SCH 46814
9 EX-101.CAL mrkr-20220930_cal.xml EX-101.CAL 40229
10 EX-101.DEF mrkr-20220930_def.xml EX-101.DEF 148322
11 EX-101.LAB mrkr-20220930_lab.xml EX-101.LAB 307334
12 EX-101.PRE mrkr-20220930_pre.xml EX-101.PRE 266564
63 EXTRACTED XBRL INSTANCE DOCUMENT mrkr-20220930x10q_htm.xml XML 901721
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37939 | Film No.: 221377001
SIC: 2834 Pharmaceutical Preparations